

PULMONARY DISEASE IN COVID-19

Y. I. Feshchenko, O. A. Golubovska, A. Y. Dziublyk, V. K. Gavrysyuk, Y. A. Dziublyk, I. V. Liskina

Abstract

The mainstay of pathogenesis of COVID-19 is based on cell damage caused by direct cytopathogenic effect of SARS-CoV-2 and excessive immune response on viral replication. Lung disease, as a major manifestation of COVID-19, is characterized by certain morphological, clinical, laboratory findings and requires specific management.

COVID-19 pathogen virology, lung morphology and radiological semiotics are presented in current review. It is important to distinguish between primary viral and secondary viral-bacterial pneumonia using a list of clinical and instrumental differential diagnosis criteria, proposed by the authors of the article.

Antiinflammatory pathogenetic therapy, which includes corticosteroids plays a leading role in treatment of COVID-19 patients. The development of secondary viral-bacterial pneumonia necessitates the administration of antibacterial therapy, which should be guided by national community-acquired pneumonia treatment recommendations. A development of COVID-19 vaccines is among the priority topics of scientific research. Medical and operational crisis cause by novel coronavirus disease determines the need in improvement of anti-epidemic measures at different levels (hospital, country, world) and modernization of healthcare system itself and its funding.

Key words: COVID-19, SARS-CoV-2, community-acquired pneumonia, diagnostics, treatment, prophylaxis.

Ukr. Pulmonol. J. 2021;1:5–14.

Yurii I. Feshchenko

Director of National Institute of phthysiology

and pulmonology named after F. G. Yanovskii

National Academy of medical sciences of Ukraine

Academician of NAMS of Ukraine, professor

03038, Kyiv, 10, M. Amosova str.

Tel.: 380 44 275 0402, fax: 380 44 275 2118

admin@ifp.kiev.ua